Control in the Middle (Cim) for Three-Period Crossover Studies Academic Article uri icon

abstract

  • Three-period crossover studies can be efficient and convenient methods of conducting Phase II clinical trials. Non-randomly placing control in the middle (CIM) has not been practiced but may be extremely useful in studies testing herbal products for which placebos are not available, or for distinguishing between behavioral and biological effects. Furthermore, this design can serve as a valuable addition to classical studies of either (a) two competing treatments or (b) treatment versus placebo versus an open label "nothing" as the control. Therefore, we propose rigorous designs that will help practitioners efficiently answer research questions where (1) two active treatments need to be compared against each other with treatment vs. placebo comparisons being of secondary importance; (2) a single active treatment needs to be tested where no placebo is available; or (3) the placebo effect is of interest in a treatment vs. placebo trial. For studies where no placebo is available, deception will be required, with participants told that in one randomly selected period (#1 or #3) they will receive the active treatment, and that they will receive a new experimental inert placebo in the other period. Assuming this design is approved by an ethics committee, it can be very useful in biomedical research.

publication date

  • 2011-09-01

NIH Manuscript Submission System ID

  • NIHMS357762

PubMed Central ID

  • PMC3296130

Web of Science ID

  • 000294481300002

grantCited

  • 1UL 1RR029890
  • K23 AT004251-02
  • K23 AT004251-03
  • K23AT004251
  • M01RR00082
  • U54RR025208
  • UL1 RR029890-01
  • UL1 RR029890-02

PubMed ID

  • 21509714

start page

  • 1473

end page

  • 1476

volume

  • 77